BidaskClub lowered shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) from a hold rating to a sell rating in a research note issued to investors on Tuesday, August 8th.
A number of other equities analysts have also issued reports on the company. Vetr lowered Teva Pharmaceutical Industries Limited from a hold rating to a sell rating and set a $31.05 target price on the stock. in a research report on Thursday, June 22nd. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a hold rating in a research report on Thursday, June 22nd. Maxim Group reaffirmed a hold rating and issued a $35.00 target price on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Royal Bank Of Canada reiterated an outperform rating and issued a $38.00 price target (down from $42.00) on shares of Teva Pharmaceutical Industries Limited in a report on Monday, May 15th. Finally, Wells Fargo & Company reiterated a hold rating on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday, June 27th. Three equities research analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $36.73.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 1.17% on Tuesday, reaching $17.30. 9,162,890 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $27.46 and a 200-day moving average of $30.98. The stock’s market cap is $17.58 billion. Teva Pharmaceutical Industries Limited has a one year low of $16.81 and a one year high of $53.96.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business’s revenue was up 12.9% on a year-over-year basis. During the same period last year, the firm posted $1.25 earnings per share. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Teva Pharmaceutical Industries Limited (TEVA) to Sell” was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/19/bidaskclub-lowers-teva-pharmaceutical-industries-limited-teva-to-sell-updated.html.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 14th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.085 per share. The ex-dividend date is Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.97%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is -18.95%.
A number of large investors have recently added to or reduced their stakes in TEVA. Capital Research Global Investors boosted its stake in Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after buying an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after buying an additional 6,685,844 shares in the last quarter. FMR LLC boosted its stake in Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after buying an additional 6,115,853 shares during the period. Northern Cross LLC boosted its stake in Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock valued at $591,169,000 after buying an additional 2,184,172 shares during the period. Finally, Nordea Investment Management AB boosted its stake in Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after buying an additional 311,894 shares during the period. 56.04% of the stock is owned by hedge funds and other institutional investors.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.
